Real-World Evidence Studies
Real-World Evidence (RWE) is clinical evidence derived from Real-World Data (RWD)—data routinely collected in clinical practice from electronic health records, insurance claims, patient registries, and other healthcare sources. Formalized by the FDA in 2016 (Sherman et al.), RWE addresses a critical gap: while randomized trials test drugs under ideal conditions, RWE evaluates how treatments actually work in diverse, real patients with comorbidities, competing medications, and varied adherence. RWE complements (not replaces) trial evidence, accelerating regulatory decision-making and supporting post-market surveillance.
出典記録
引用は手法の出典記録からそのままコピーされています。それらからレベルごとの検証は推論されません。
- Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., ... & Califf, R. M. (2016). Real-world evidence—what is it and what can it tell us? New England Journal of Medicine, 375(23), 2293–2297. · DOI 10.1056/NEJMsb1609216
- Levitan, B., Chan, E. W., Doshi, J. A., Hines, P., Komattireddy, H., Sanchez, R., & Sheridan, S. (2018). Collaboration and competition between real-world data and clinical trials. Therapeutic Innovation & Regulatory Science, 52(2), 172–176. · URL
- FDA (2021). Strengthening Our National Strategy on Adaptive Learning Systems for Health Care Quality and Safety: Report to Congress. US Food and Drug Administration. · URL
キュレーションされた主張
主張は証拠台帳に永続化され、それぞれが独自の評価を持っています。
このビューは、台帳に主張評価がない場合、主張評価を生成しません。
関連手法
手法グラフから生成され、機械が提案した関係として表示されます — 証拠主張は推論されません。